GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.

Trial Details

NCT ID
NCT07627191
Phase
EARLY_PHASE1
Sponsor
University of Arizona
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • GLP1-RA (semaglutide)
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648

Key Eligibility Criteria

  • Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Pleas…
  • The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease)
  • Measurable disease per RECIST v1.1 as determined by the investigator
  • Patients must be appropriate candidates for first-line, SOC treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →